Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations

Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations


The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020.

Mike Blake | Reuters

A Delaware federal court jury on Tuesday cleared Gilead Sciences of civil claims by the U.S. government that the company violated patents held by the Centers for Disease and Prevention for an HIV prevention drug.

The government sued Gilead in 2019, arguing that the company was profiting off CDC patents through the company’s sales of Truvada and Descovy, oral medications taken to prevent HIV infection.

But jurors after a multi-day trial found that the government’s patent claims on the HIV prevention regimen called pre-exposure prophylaxis, or PrEP, were not valid.

“Today’s decision confirms our longstanding belief that we have always had the rights to make Truvada and Descovy for PrEP available to all who need it,” said Gilead general counsel Deb Telman in a statement.

“Gilead will continue to champion collaborations, including our efforts with the U.S. Health and Human Services Department (HHS) and CDC that span more than 15 years, as we all work together toward our common goal to end the HIV epidemic for everyone, everywhere,” Telman said.

HHS, the parent entity of CDC, did not immediately respond to a request for comment on the verdict.

Gilead’s combined worldwide sales of Truvada and Descovy were about $2 billion in 2022, according to company financial statements.

The government claimed that the CDC in the mid-2000s discovered that two drugs, emtricitabine and tenofovir, were highly effective in preventing HIV infection.

Truvada and Descovy both contain emtricitabine and tenofovir. But Gilead said it invented these drugs, and that the concept of using Truvada to prevent HIV was well known when the U.S. government filed for the patents.

PrEP has played a crucial role in reducing the number of new HIV infections in communities that face a higher risk from the virus, such as men who have sex with other men.

Scientists have tried for decades to develop a vaccine against HIV. But those efforts to date have been unsuccessful.

About 40 million people worldwide have died from HIV since the epidemic began in the 1980s, according to the World Health Organization. More than 80 million people have been infected.

In 2021, there were 38 million people living with HIV, according to the WHO data.



Source

Yum Brands is cooking up more than fast food. It’s preparing the industry’s next CEOs
Business

Yum Brands is cooking up more than fast food. It’s preparing the industry’s next CEOs

Customers walk out of a Taco Bell and Pizza Hut restaurant during lunchtime in Los Angeles, California. Kevork Djansezian | Getty Images Looking for the next CEO for your restaurant chain? Try mining the ranks at Yum Brands. The restaurant conglomerate, which owns Pizza Hut, KFC and Taco Bell and reported quarterly results Tuesday, has […]

Read More
AI is already impacting the labor market, starting with young tech workers, Goldman economist says
Business

AI is already impacting the labor market, starting with young tech workers, Goldman economist says

A screen displays the the company logo for Goldman Sachs on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 7, 2025. Brendan McDermid | Reuters Changes to the American labor market brought on by the arrival of generative AI are already showing up in employment data, according to […]

Read More
Roku launches ad-free streaming service, Howdy, for .99 a month
Business

Roku launches ad-free streaming service, Howdy, for $2.99 a month

A Roku remote in an arranged photograph in Hastings-on-Hudson, New York, on May 2, 2021. Bloomberg |Getty Images Roku announced Tuesday it’s launched Howdy, a commercial-free streaming service that costs $2.99 a month, in a shift for the company that’s long been know for free, ad-supported viewing. The streaming platform is expected to feature 10,000 […]

Read More